Abstract
Interleukin (IL)-10 was trialled as an anti-inflammatory therapy for inflammatory human diseases. However, IL-10 increases B cell proliferation and antibody production, which limits its therapeutic use. Thus modifying these effects may improve efficacy. Using blood-derived B cells to screen these effects is limiting, due to ethical considerations and varied donor responses.
Therefore, this study aimed to evaluate Raji and Daudi B cell-lines as models of blood-derived B cell responses to IL-10.